pelabresib

Novartis: launch of Morphosys drug by could be 2027 or later
Pharma Live
Thu, 11/21/24 - 11:43 am
Novartis
pelabresib
MorphoSys
obesity
Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years
Fierce Biotech
Tue, 10/29/24 - 11:44 am
Novartis
MorphoSys
M&A
AML
pelabresib
Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing
Fierce Biotech
Fri, 04/12/24 - 11:23 am
Novartis
MorphoSys
pelabresib
myelofibrosis
M&A
BET inhibitor
MorphoSys’ pelabresib meets endpoints in Phase III myelofibrosis trial
Clinical Trials Arena
Tue, 11/21/23 - 11:55 am
MorphoSys
clinical trials
pelabresib
myelofibrosis